Developmental Focus on Disorders of Sex Development: Special Issue Overview

L. S. Freund, S. Taymans, E. Wehr, C. A. Stratakis

Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, USA

Disorders of Sex Development (DSD) – a broad array of conditions of differing etiologies in which the development of chromosomal, gonadal, or phenotypic sex is atypical, including the condition of ambiguous genitalia – has only recently been part of the clinical nomenclature [1]. It is still not considered ideal terminology by those affected by DSD nor do all clinicians or researchers agree that it is the best term to use for the wide range of conditions that fall under this diagnostic category. The data on the incidence of DSD are sparse, but it is estimated that the prevalence is one in 4500–5000 in the general population or even higher, if one includes subtle hormonal changes that affect gonadal function [2]. There have been advances in our understanding of the pathophysiology of these disorders, but we still lack an evidence base of 1) short and long-term outcomes from newer surgical techniques, 2) the efficient use of available genetic and molecular diagnostic tools, and 3) optimal treatment with exogenous hormones. Equally important is the need to expand our understanding of the developmental implications of DSD for the child and the impacts on the family of children with DSD. We know very little about the impact of DSD during different periods of development on the affected child and on the child’s family, which can have important implications for the timing and nature of clinical interventions as well as the overall health and wellbeing of children and families affected by DSD.

To date, the literature on DSD has focused largely on endocrinology, urology, and genetics. To the limited extent that the field has addressed child and adolescent development, it has focused almost exclusively on individual psychosexual outcomes [3]. To stimulate research on developmental dimensions in DSD care, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), with additional support from the Office of Research on Rare Diseases of the National Institute of Health’s National Center for Advancing Translational Sciences, convened a scientific workshop: “Growing up with DSD: Critical Developmental Issues for Children and Families Affected by Disorders of Sex Development”, on March 26–27, 2014, in Bethesda, Maryland, USA [4]. Experts from a wide range of disciplines were invited and representation from an “umbrella” group of advocacy organizations was included to spark discussion and inform NICHD about research priorities in the area of DSD. The workshop included sessions on diagnostic factors associated with quality of life outcomes for patients at different developmental stages, decision-making in the context of gender assignment or other DSD treatments, the psychosocial aspects of living with DSD, clinical management and social factors associated with quality of life outcomes, and examples of research with other typical and atypical developmental conditions, that can inform research and clinical management of DSD. It is from this workshop that this special issue in Hormone and Metabolic Research was conceived.

The articles included in this special issue correspond to several of the presentations made at the March 2014 NICHD workshop. Article topics fall within several broad categories related to development and DSD including, current biomedical techniques, the interface between affected child and family and the medical community, the psychosocial and gender development issues for children and adolescents with DSD and their families, and clinical research approaches with a developmental focus. The special issue ends with an assessment of how the field has progressed since the 2006 Chicago DSD Consensus [2].

The series of article starts with recent advances in chromosomal microarray and exome sequencing technologies for diagnosing DSD that are reviewed by Hayk Barseghyan, Emmanuèle Délot, and Eric Vilain [5]. These techniques have allowed
for greater efficiency and higher rates of successful diagnosis of DSD. The authors propose a new model for clinical diagnosis of DSD using exome sequencing as a first-stage diagnostic technique. Michael DiSandro, Richard Rink, and Deborah Merke [6] describe current surgical techniques and medical management of DSD. The authors consider these newer approaches within a developmental perspective and point out that there is little evidence to either support early surgery to “normalize” atypical genital appearance or to delay such surgery. Jennifer Dietrich [7] reviews the variable presentation of congenital reproductive tract anomalies that raise surgical, gynecologic and obstetric concerns and that, in some cases, may co-occur with renal, spinal or other malformations that must be evaluated simultaneously. She notes the lack of consensus about treatment of different congenital reproductive tract anomalies and the need for data on short- and long-term outcomes.

An important aspect of what was discussed at the meeting was the interface between affected child and family and the medical community: It is difficult to imagine the weight of responsibility for parents in deciding gender assignment and considering genitaloplasty for a child born with DSD. Laura Siminoff and David Sandberg [8] review the complementary roles of shared decision-making, decision aids and support tools (DASTS) in assisting health care providers and caregivers in considering clinical options when a child with DSD is born. The authors are currently developing a tool with support from the Patient-Centered Outcomes Research Institute [9]. Alexander Kon [10] examines ethical principles related to early gender assignment and genitaloplasty for infants with DSD. He suggests that early interventions may not be in a child’s best interest, given reports from adults with DSD of adverse outcomes of earlier surgery techniques as well as later gender identification that differs from that assigned earlier in development. In addition, he discusses an ethical obligation to safeguard a child’s right to an “open future.”

The article by Amy Lossie and Janet Green [11] is written from the viewpoint of DSD patient advocate priorities. They describe the role of activism in moving the medical community from a DSD standard of care based on early patient “fixes” and non-disclosure of medical information to patients, to the 2006 DSD consensus statement, which emphasizes multi-disciplinary care, questions evidence for many standard procedures, and promotes the inclusion of fully informed patients in their own medical decision-making. Lossie and Green further identify multiple challenges to be met in developing the capacity of affected individuals and families, researchers and clinicians to work together collaboratively to improve care for DSD.

Psychosocial and gender development issues for children and adolescents with DSD and their families are reported by Anna Nordstrom [12] who reviews literature on quality of life (QoL) and psychosocial outcomes in DSD. Follow-up studies have often focused on surgical results, sexual function and psychosexual outcome and indicated unsatisfactory results in many cases, while epidemiological studies indicate that for some diagnostic groups, there is less than optimal psychosocial outcome. William Bukowski, Elizabeth McCauley, and Thomas Mazur [13] discuss the psychological challenges to successful development that children and adolescents with DSD might face, and they note substantial limitations in the literature on this subject. They identify multiple research needs, including studies of the developmental trajectories of persons with DSD, and factors that promote a sense of self-typicality, even in the face of atypical development. Sheri Berenbaum and Heino Meyer-Bahlburg [14] discuss physiological and psychological processes and outcomes of gender development and sexuality in individuals with DSD, with a particular focus on the effects of sex hormones during different developmental periods, together with experiential factors and social contexts. They identify a series of key research questions, including how to account for variable outcomes and how gendered characteristics affect other aspects of quality of life.

Adolescence is the focus of the article by Richard Auchus and Elizabeth Quint [15]. The authors describe the multiple challenges that adolescence presents to individuals with DSD, their families and the clinicians responsible for their care. Such challenges relate to adolescents’ increasing independence, their access to care, and changes in clinical providers as they move through early, middle and late stages of adolescent development and transition from pediatric to adult clinicians.

The impact on caregivers of children with DSD is addressed by Amy Wisniewski and David Sandberg [16]. They report preliminary data on the psychosocial comorbidities in such caregivers including feelings of stigma, isolation, stress, anxiety and depression. The authors identify a need for interventions to ameliorate caregivers’ psychosocial comorbidities so as to optimize the social adjustment, mental health and health-related quality of life of both patients and families of children with DSD.

Clinical research approaches with a developmental focus are addressed by Grayson Holmbeck and Cassandra L. Aspinall [17] who describe how developmentally-oriented research methods and clinical management strategies for congenital conditions (e.g., spina bifida and craniofacial anomalies) can be applied to research and management of children with DSD. The challenges families and patients face with such conditions (including DSD) pose important areas of research and clinical management questions in terms of how the conditions impact child and family well-being and optimal development.

David Sandberg and Amy Wisniewski [18] note that North American and European professional organizations recognize that optimal care for those with DSD requires a broad range of expertise found typically only at tertiary health care centers. They describe current research networks focused on DSD health care delivery and outcomes, discuss opportunities for and barriers to standardization in research, and emphasize the need to integrate patient and family perspectives.

This special issue of Hormone and Metabolic Research ends with an assessment of how the field has progressed since the 2006 Chicago DSD Consensus, authored by Leuan Hughes [19], one of the key contributors to that Consensus Statement [2]. Hughes provides a personal perspective on the impact of the 2006 Chicago Consensus meeting on DSD clinical practice and research. He comments on nomenclature and DSD classification, multidisciplinary team working, efforts to reach a causative diagnosis of DSD, the value of case registries, and the potential for meaningful clinical outcome studies and basic research.

It is the intention of this collection of articles to highlight a continuing focus on children, adolescents and young adults with DSD and their families. As the authors in this special issue point out, much further research is needed. Both research and clinical management need to be multidisciplinary, while maintaining a developmental focus, and include patient and caregivers as partners in care. It is encouraging to see a recent article by pediatric endocrinologists, pediatricians, and a pediatric surgeon call for multidisciplinary teams, including those specialists along with psychologists, developmental specialists and trained peer sup-
port to cooperate in the management of patients with DSD [20]. These integrated approaches hold the greatest promise of addressing the challenges of DSD and for maximizing the well-being of individuals with DSD.

It should be noted that the understanding of issues of patients with DSD and their well-being, and the elucidation of numerous questions surrounding sex hormone action go beyond what is being discussed in this special issue. The reader is also directed to a number of other articles, both reviews and original research that have been published in this (and other journals) [21–30] for many of the subjects that relate to sex hormone secretion, action, and their phenotypic effects, as well as the corresponding clinical implications from common or subtle 21-hydroxylase defects [21–23], to hypogonadism-coexisting morbidities [24], the sexual dimorphism of other endocrine secretions [25], the developmental effects of early exposures to androgens or estrogens or deficient responses to their action [26–28], and their metabolic effects [29,30].

Statement

Comments and the views of the authors do not necessarily represent the views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Acknowledgements

This work was supported, in part, by the Intramural and Extramural Research Programs of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

References

4 Growing up with Disorders of Sex Development (DSD): Critical developmental issues for children and families affected by DSD. 2014; http://www.nichd.nih.gov/about/meetings/2014/Pages/032714.aspx
8 Siminoff IA, Sandberg DE. Promoting shared decision making in disorders of sex development (DSD): decision aids and support tools. Horm Metab Res 2015; 47: 335–339
10 Kon AA. Ethical issues in decision-making for infants with disorders of sex development. Horm Metab Res 2015; 47: 340–343
11 Looise AC, Green J. Building trust: the history and ongoing relationships amongst DSD clinicians, researchers, and patient advocacy groups. Horm Metab Res 2015; 47: 344–350
15 Aucush RJ, Quinl EH. Adolescents with disorders of sex development (DSD) – lost in transition? Horm Metab Res 2015; 47: 367–374
17 Holmbeck GN, Aspinall CL. Disorders of sex development: lessons to be learned from studies of spina bifida and craniofacial conditions. Horm Metab Res 2015; 47: 380–386
21 Moura-Massari VO, Bugamo JD, Marcondes JA, Gomes LG, Mendonça BB, Bachega TA. CYP21A2 genotypes do not predict the severity of hyperandrogenic manifestations in the nonclassical form of congenital adrenal hyperplasia. Horm Metab Res 2013; 45: 301–307
28 Silva TS, Richeti F, Cunha DP, Amarante AC, de Souza Leão JQ, Longui CA. Androgen receptor mRNA measured by quantitative real time PCR is decreased in the urethral mucosa of patients with middle idiopathic hypospadias. Horm Metab Res 2013; 45: 495–500
30 Tena-Sempere M. Interaction between energy homeostasis and reproduction: central effects of leptin and ghrelin on the reproductive axis. Horm Metab Res 2013; 45: 919–927